A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity
- 9 March 2004
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 75 (3) , 223-233
- https://doi.org/10.1016/j.clpt.2003.10.006
Abstract
To clarify the molecular determinants of the metabolic variability of morphine, we searched for genetic polymorphisms in the gene for uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) and evaluated their functional impact in vitro and in patients with cancer receiving long-term morphine therapy. Genetic analysis revealed the existence of 8 single-nucleotide polymorphisms (SNPs), 6 of which are tightly linked and are at positions -1248, -1241, -1054, -842, -268, and -102 relative to the hepatic start site. In contrast, an SNP at position -66 occurs independently, whereas a novel variation at position -79 appears to be in linkage disequilibrium with the codon 268 SNP (UGT2B7*2). At least 4 haplotypes were observed in white subjects included in the initial SNP screening. On functional in vitro characterization, promoter-reporter gene constructs with the -79 variation displayed 2.5- to 7-fold less activity compared with the wild-type construct in Caco-2 colon cells and HepG2 hepatoma cells, respectively (P =.015 and P <.001, respectively). To investigate a possible effect of the -79 variation in vivo, serum morphine and morphine glucuronide concentrations were measured by liquid chromatography-mass spectrometry in patients with cancer who received long-term oral morphine therapy, and subjects were then genotyped for the -79 polymorphism. Among 175 patients with normal hepatic and renal function, 6 were heterozygous for the -79 variation, and the morphine-6-glucuronide (M6G)/morphine and morphine-3-glucuronide (M3G)/morphine ratios versus those in the 169 noncarriers were 5.9 +/- 3.5 versus 7.1 +/- 7.0 for M6G/morphine (P =.96) and 31.2 +/- 17.1 versus 42.9 +/- 31.2 for M3G/morphine (P =.53), respectively. Further studies in larger samples are needed to make conclusions about the possible clinical relevance of the -79 polymorphism in the UGT2B7 gene.Keywords
This publication has 29 references indexed in Scilit:
- Relationships Among Morphine Metabolism, Pain and Side Effects During Long-Term TreatmentJournal of Pain and Symptom Management, 2003
- Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patientsThe Pharmacogenomics Journal, 2003
- Morphine-6-glucuronide, a potent mu agonistPublished by Elsevier ,2002
- Hepatocyte Nuclear Factor-1α Is a Causal Factor Responsible for Interindividual Differences in the Expression of UDP-Glucuronosyltransferase 2B7 mRNA in Human LiversDrug Metabolism and Disposition, 2002
- Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small IntestineJournal of Biological Chemistry, 2000
- Systematic review of factors affecting the ratios of morphine and its major metabolitesPain, 1998
- Glucuronidation of Morphine in Human Kidney MicrosomesBasic & Clinical Pharmacology & Toxicology, 1988
- Human brain metabolism of morphine and naloxonePain, 1988
- Presystemic glucuronidation of morphine in humans and rhesus monkeys: subcellular distribution of the UDP-glucuronyltransferase in the liver and intestineXenobiotica, 1986
- Isolation and Identification of Morphine 3- and 6-Glucuronides, Morphine 3,6-Diglucuronide, Morphine 3-Ethereal Sulfate, Normorphine, and Normorphine 6-Glucuronide as Morphine Metabolites in HumansJournal of Pharmaceutical Sciences, 1977